based mixed GIP for the treatment of metabolic disorders and obesity agonists

Glucagon analog (SEQ ID NO: 1) having agonistic activity GIP, with the following modifications: (a) an amino acid modification at position 1 that confers agonist activity GIP, optionally, wherein the amino acid at position 1 is an amino acid lacking an imidazole side chain; (B) one, two, three or all amino acids at positions 16, 20, 21 and 24 of the analog is substituted with an amino acid, a-disubstituted, (c) amino acid modifications at one, two or all positions 27 28 and 29, and (d) 1-9 further amino acid modifications relative to the glucagon sequence (SEQ ID NO: 1), wherein the EC50 of the analog for GIP receptor activation is aproximadamentre 10 nM or less, and wherein the EC50 of the analog in the GIP receptor is less than about 50 times different from its EC50 at the GLP-1, optionally wherein the power GIP analog is within about 15 times power GLP-1 analog.